| Effect of dulaglutide on glucose metabolism and bone metabolism in patients with type 2 diabetes mellitus complicated with osteoporosis |
| Received:April 21, 2020 Revised:June 29, 2020 Click here to download the full text |
| Citation of this paper:YAO Hu,ZOU Jun-jie.Effect of dulaglutide on glucose metabolism and bone metabolism in patients with type 2 diabetes mellitus complicated with osteoporosis[J].Chinese Journal of Clinical Medicine,2020,27(5):801-805 |
| Hits: 1210 |
| Download times: 446 |
|
| Abstract:Objective: To explore the effect of dulaglutide on glucose metabolism and bone metabolism in patients with type 2 diabetes mellitus complicated with osteoporosis. Methods: From May 2019 to February 2020, 80 patients with type 2 diabetes mellitus complicated with osteoporosis were treated and selected. According to different treatment methods, they were divided into two groups: the observation group (n=36) and the control group (n=44). The control group was treated with oral alendronate, vitamin D3, subcutaneous injection of aspartic insulin 30 and so on. The observation group was treated with subcutaneous injection of 0.75 mg dulaglutide on the basis of the control group, once a week. After 3 months of treatment, the body mass index (BMI), glucose metabolism index (FPG, 2hPG, HbA1c), osteoporosis related factors (bone mineral density, osteocalcin, P1NP, β-CTX), and bone metabolism index (ALP, BAP, OPG) of the two groups were compared before and after treatment, and the adverse reactions rates were calculated. Results: After treatment, FPG, 2hPG, and HbA1c in the two groups were significantly lower than before treatment (P<0.05), and the indexes in the observation group were significantly lower than those in the control group (P<0.05). The BMD and osteocalcin levels in the two groups were increased, and the levels in the observation group were significantly higher than those in the control group (P<0.05). The PINP and β-CTX levels in the two groups were significantly decreased (P<0.05), and the P1NP and β-CTX levels in the observation group were significantly lower those in the control group (P<0.05). Conclusions: Dulaglutide combined with insulin can effectively control blood glucose, improve bone metabolism, and increase bone density in patients with type 2 diabetes mellitus complicated with osteoporosis. |
| keywords:dulaglutide insulin type 2 diabetes mellitus osteoporosis |
| HTML View Full Text View/Add Comment Download reader |
|
|
|